New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers

NCT ID NCT03505554

Completed Disease control Sponsor: University of Milano Bicocca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also tracked side effects, quality of life, and how long patients lived without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib (oral drug)
What this could lead to: If it works, this could offer a new treatment option for patients with ALK-positive lymphoma that has stopped responding to other ALK inhibitors.
What could go wrong: This is a very small, early-phase trial with only 9 participants, so results may not apply to everyone. The drug may cause side effects and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-positive anaplastic large cell lymphoma anaplastic large cell lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE

Contacts and locations

Locations

Irccs San Gerardo Dei Tintori

Monza, Italy/MB, 20900, Italy
UOC Ematologia, Ospedale S. Eugenio

Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.